NGINX Simplifies the Journey to Microservices
NGINX, Inc., the company based on the popular open source project and offering a suite of technologies designed to develop and deliver modern applications, today announced new capabilities and major enhancements to its Application Platform – an integrated suite of software technologies that simplify the adoption and deployment of microservices.
Enterprise adoption of microservices has reached a tipping point. More than half of companies in a recent survey indicated they deployed microservices for at least one application, and 26% are doing so in production.* Companies are looking to microservices as a modern application architecture to support digital business efforts. However, the transition to microservices is complex and requires enterprises to balance development and delivery across a mix of legacy, monolithic applications and newer, open-sourced based microservices environments.
“Digital transformation makes application modernization imperative for enterprises. Most popular, modern apps are created by cloud-native companies using predominantly open source technologies,” says Gus Robertson, CEO, NGINX. “However, enterprises struggle to implement these same technologies to create compelling customer experiences. To cross this digital divide, enterprises must adopt a microservices architecture that complements their legacy applications. We believe NGINX has the technology to accelerate their journey into microservices.”
NGINX is one of the most ubiquitous software technologies for modern application architectures. More than 11 million new domains launch on NGINX open source each month, an average of 4 every second. Users have pulled a billion NGINX instances from the Docker Store, including over a million pulls of the NGINX Kubernetes Ingress controller. With this footprint, NGINX has established a leadership position in enterprises adoption of microservices. More than 3 million NGINX instances and 250 customers are deployed in production microservices environments.
Simplifying Enterprise Application Architectures
NGINX's lightweight technologies provide a scalable data and control plane that deliver applications across bare metal, VM, container, and public cloud infrastructures. The NGINX Application Platform collapses ten disparate functions into a single, integrated solution: web server, application server, load balancer, reverse proxy, caching, web application firewall, API gateway, ingress controller, sidecar proxy, and service mesh controller. NGINX eliminates the complexity of separate tools, accelerating microservices adoption and freeing up resources to focus on app development instead of infrastructure management.
Capabilities to Further Accelerate Microservices Adoption
With today’s announcement, the NGINX Application Platform capabilities extends to include:
- New control-plane solution to manage both legacy and microservices apps. NGINX Controller R1 (available Q2, 2018) introduces new monitoring dashboards, alerting, and management of NGINX software. The Controller architecture is extensible and designed to integrate additional control-plane solutions like Istio, eliminating the need for enterprises to deploy multiple frameworks to manage a service mesh.
- New app server to improve performance for modern microservices code. NGINX Unit 1.0 (available April 12, 2018) is a production-ready open source app server. Unit simplifies microservices deployments by supporting multiple languages in a single server, including Go, Perl, Python, PHP, and Ruby. Unit is a developer-friendly, high performance architecture that dynamically configures via an API.
With well-tested products and proven success, NGINX offers enterprises the technologies and expertise at every stage of their journey toward a fully implemented microservices architecture.
About NGINX, Inc.
NGINX, Inc. is the company behind the popular open source project trusted by more than 450 million sites. We offer a suite of technologies for developing and delivering modern applications. The NGINX Application platform allows enterprises undergoing digital transformation to modernize legacy, monolithic applications as well as deliver new, microservices-based applications. Companies like Netflix, Starbucks, and McDonalds rely on NGINX to reduce costs, improve resiliency, and speed innovation.
We are headquartered in San Francisco, with our EMEA head office in Cork, Ireland and APAC head office in Singapore. Learn more at https://www.nginx.com/
*Cited from DZone study
PAN Communications for NGINX
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme